
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Tempus
Deal Size : Undisclosed
Deal Type : Collaboration
Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment
Details : Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Tempus
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Induced Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Novecite
Deal Size : $56.0 million
Deal Type : Licensing Agreement
Details : NoveCite will develop and commercialize Novellus's iMSCs to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $5.0 million
October 13, 2020
Lead Product(s) : Induced Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Novecite
Deal Size : $56.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Novellus, a Cambridge, Mass-based cell engineering company, has developed patented, non-immunogenic mRNA-based induced mesenchymal stem cell (iMSC) platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pontifax Medison Debt Financing
Deal Size : $57.0 million
Deal Type : Series C Financing
Novellus Closes $57M Series C Financing
Details : Proceeds will fund the clinical development of PLX-8394 for patients with BRAF fusions and glioma patients with BRAF mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 21, 2020
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pontifax Medison Debt Financing
Deal Size : $57.0 million
Deal Type : Series C Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Plexxikon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394
Details : Under the terms of the agreement, Plexxikon grants Novellus rights to research, develop, manufacture and exclusively commercialize PLX8394 worldwide.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 03, 2020
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Plexxikon
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19
Details : Citius signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome from a subsidiary of Novellus.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 01, 2020
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
